1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Approvals

Podcast: Noticing Neffy – A ‘Transformative Treatment’ For Type 1 Allergies

 
• By Anabel Costa-Ferreira

Richard Lowenthal, co-founder and CEO of ARS Pharmaceuticals, highlights the crucial unmet need for needle-free devices to treat type 1 allergic reactions, given challenges associated with current epinephrine injectors. Hear what’s next for the Neffy intranasal spray and ARS Pharmaceuticals.

In Vivo Podcast

[Editor’s note: This article appeared first in our sister publication, In Vivo.]

After a long-awaited series of research phases and trials, the FDA recently granted approval for Neffy as the ‘First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis.’

Speaking to In Vivo, Richard Lowenthal, co-founder and CEO of ARS Pharmaceuticals, Inc., looked back at successes and challenges across Neffy’s development, addressing the range of factors that led to this unmet area of need, including challenges posed by epinephrine auto-injectors.

Taking the EpiPen as a point of comparison, Lowenthal highlighted the efficacy and accessibility of Neffy as key factors with the potential to improve patient outcomes and identified points of action that ARS is hopeful to take across the next year.

From developing a lower-dose Neffy for children below 30kg to seeking regulatory approval in the UK, Canada, China, Australia, New Zealand, and Japan, the future appears bright for this growing biotech.

Timestamps:

1:04 History And Development of ARS Pharma

2:50 Where has this unmet need come from?

12:30 Making Neffy suitable for children >15kg

14:30 Trial stages and approvals

18:12 Why switch to Neffy?

23:22 Recent FDA approval

29:34 Future of ARS pharma and upcoming goals

More from Approvals

Quibim Extends Into US Market With FDA Authorization Of QP-Prostate CAD

 
• By Natasha Barrow

The US FDA's clearance of QP-Prostate CAD positions the company to support US health care providers and growing markets for fusion biopsy and focal therapy, said Quibim CEO and founder Angel Alberich-Bayarri.

Dexcom Eyes US FDA Clearance For 15-Day CGM, But Insurance Coverage Remains Uncertain

 
• By Shubham Singh

Tempering expectations on the immediate market impact for the upgraded continuous glucose monitor, Dexcom notes insurance coverage and pump integrations will take time to finalize.

Sebela’s Miudella Is First Hormone-Free IUD To Win FDA Approval In 40 Years

 
• By Elizabeth Orr

The device, which uses a flexible frame to ease insertion and minimize the dose of copper, is 99% effective in preventing pregnancy. Clinical trial lead David Turok said it represents “a real advance” in contraceptive options.

Medtronic Widens Parkinson’s aDBS Opportunity With Key US Approvals

 
• By Natasha Barrow

Medtronic’s US FDA approval for BrainSense aDBS and BrainSense EI software features of the Percept neurostimulator device has quickly followed CE marking in January.

More from Leadership

Research Finds Benefit From DME Suppliers For People Living With Diabetes

 
• By Elizabeth Orr

People living with diabetes who receive continuous glucose monitors (CGMs) through medical supply firms show higher compliance, lower costs of care, and fewer hospitalizations after one year than those who use pharmacies, a new study shows.

Barcelona’s S2 Xpeed Accelerates Hardware-Based Medtech Start-Ups From Prototype To Market

 
• By Marion Webb

Barcelona-based accelerator S2 Xpeed is driving the rapid growth of medtech and hardware start-ups in Europe. Operating under a "sweat equity" model, the program helps early-stage companies move from prototype to manufacturing readiness in exchange for equity. This month, the accelerator will add a fourth cohort of 10 more start-ups, five of which are in the medtech space.

Wired Health: Women Of Wearables Shares Market Outlook

 
• By Natasha Barrow

Medtech Insight sat down with Anja Streicher, chief marketing officer at Women of Wearables, a global community offering events and education resources to support the femtech industry, to discuss trends in the women's wearables tech market, challenges and innovators pushing the boundaries.